US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NervGen Pharma Corp.

1.76

-0.1500-7.85%

Post-market: 1.800.0400+2.27%19:50 EDT

Volume:1.05M

Turnover:1.88M

Market Cap:190.08M

PE:-3.16

High:1.92

Open:1.92

Low:1.73

Close:1.91

52wk High:6.30

52wk Low:1.58

Shares:108.00M

Float Shares:95.39M

Volume Ratio:2.29

T/O Rate:1.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5570

EPS(LYR):-0.4448

ROE:-757.48%

ROA:-37.70%

PB:15.64

PE(LYR):-3.96

Loading ...

Overview Company News Filings

NervGen Pharma files $250M mixed securities shelf

NervGen Pharma Increases Mixed Shelf Offering to $250 Mln From $150 Mln - SEC Filing

THOMSON REUTERS

NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291

NervGen says NVG-291 improves gait quality in Phase 1b/2a chronic tetraplegia study

NervGen Pharma Corp - Nvg-291 Shows Statistically Significant Gait Quality Improvement in Phase 1B/2a Connect Sci Study

THOMSON REUTERS

NervGen Pharma Corp - on Track to Initiate Phase 3 Restore Study in Mid-2026

THOMSON REUTERS

NervGen Pharma (NGEN) Receives a Buy from Stifel Nicolaus

BUZZ-U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co

BUZZ-NervGen Pharma tumbles on deep-discounted $60 mln equity raise

NervGen Pharma Shares Down 22.3% at $2.86 Premarket After Public Offering

THOMSON REUTERS

BRIEF-Nervgen Says Co. Announces Pricing Of US$60.0 Million Public Offering Of Securities

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

THOMSON REUTERS

NervGen Pharma Corp - Common Shares Sold at $2.50 per Share and Warrant

THOMSON REUTERS

NervGen Pharma secondary offering; price range $2.50-$3.68

NervGen Pharma Shares Slide After Disclosing Public Offering

NervGen Pharma launches underwritten public offering of shares and warrants

NervGen Pharma Corp - Net Proceeds to Advance Nvg-291 Clinical Studies and for General Corporate Purposes

THOMSON REUTERS

NervGen Announces Proposed Public Offering of Securities

THOMSON REUTERS

NervGen Pharma Corp - Commences Underwritten Public Offering of Common Shares, Warrants, and Pre-Funded Warrants

THOMSON REUTERS

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/NGEN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NGEN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","market":"US","secType":"STK","nameCN":"NervGen Pharma Corp.","latestPrice":1.76,"timestamp":1790884800000,"preClose":1.91,"halted":0,"volume":1051255,"hourTrading":{"tag":"盘后","latestPrice":1.8,"preClose":1.76,"latestTime":"19:50 EDT","volume":92884,"amount":163932.31,"timestamp":1790898631747,"change":0.04,"changeRate":0.022727,"amplitude":0.12358},"delay":0,"changeRate":-0.07853403141361252,"floatShares":95391200,"shares":108000000,"eps":-0.557,"marketStatus":"Not Yet Opened","change":-0.15,"latestTime":"10-01 16:00:00 EDT","open":1.92,"high":1.92,"low":1.7301,"amount":1875599.0261364998,"amplitude":0.099424,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.557,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790928000000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":1.91,"preHourTrading":{"tag":"盘前","latestPrice":1.95,"preClose":1.91,"latestTime":"07:08 EDT","volume":60,"amount":117.400002,"timestamp":1790852901294,"change":0.04,"changeRate":0.020942,"amplitude":0.020942},"postHourTrading":{"tag":"盘后","latestPrice":1.8,"preClose":1.76,"latestTime":"19:50 EDT","volume":92884,"amount":163932.31,"timestamp":1790898631747,"change":0.04,"changeRate":0.022727,"amplitude":0.12358},"volumeRatio":2.290748,"impliedVol":0.0812,"impliedVolPercentile":0.2914},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","floatShares":95391200,"roa":"-37.70%","roe":"-757.48%","lyrEps":-0.444846,"volumeRatio":2.290748,"shares":108000000,"dividePrice":0,"high":1.92,"amplitude":0.099424,"preClose":1.91,"low":1.7301,"week52Low":1.58,"pbRate":"15.64","week52High":6.3,"institutionHeld":0,"latestPrice":1.76,"eps":-0.557,"divideRate":0,"volume":1051255,"delay":0,"ttmEps":-0.557,"open":1.92,"prevYearClose":5.6,"prevWeekClose":1.94,"prevMonthClose":1.91,"prevQuarterClose":1.91,"fiveDayClose":2.02,"twentyDayClose":2.33,"sixtyDayClose":1.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGEN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"NGEN","fiscalQuarterEnding":"2026/06","expectedEps":-0.09,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2026-05-15","symbol":"NGEN","fiscalQuarterEnding":"2026/03","expectedEps":-0.07,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.09},{"date":"2026-03-31","symbol":"NGEN","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774944000000,"name":null,"time":"Pre-MKt","dateTimestamp":1774929600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGEN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGEN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.875,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.875,"analysts":8,"updateTime":1784001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NGEN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NGEN","date":"2026-09-30","current":-3.159785,"percent":0.961111,"low":-25.148356,"twenty":-17.005665,"median":-9.17019,"eighty":-5.866178,"high":-4.008234,"avg":-10.794315,"sd":5.756838,"marketCap":206443455},"quantilePoints":[{"date":"2026-01-09","current":-25.148356,"twenty":-24.98651,"median":-24.743741,"eighty":-24.500973,"marketCap":463798962.95},{"date":"2026-01-16","current":-23.484013,"twenty":-24.651705,"median":-24.262661,"eighty":-23.546305,"marketCap":432253265.53},{"date":"2026-01-23","current":-22.238177,"twenty":-24.339127,"median":-23.484013,"eighty":-22.456198,"marketCap":412101315.23},{"date":"2026-01-30","current":-17.441707,"twenty":-24.262661,"median":-22.611928,"eighty":-20.307131,"marketCap":329508465.32},{"date":"2026-02-06","current":-16.382746,"twenty":-23.795472,"median":-22.238177,"eighty":-17.908896,"marketCap":306238051.42},{"date":"2026-02-13","current":-17.441707,"twenty":-23.484013,"median":-19.886661,"eighty":-17.285978,"marketCap":327197651.85},{"date":"2026-02-20","current":-18.220355,"twenty":-23.359429,"median":-18.282647,"eighty":-17.285978,"marketCap":340388899.6},{"date":"2026-02-27","current":-17.753166,"twenty":-22.879782,"median":-18.03348,"eighty":-17.410561,"marketCap":331850071.27},{"date":"2026-03-06","current":-17.223686,"twenty":-22.51849,"median":-17.893323,"eighty":-17.27352,"marketCap":321208516.98},{"date":"2026-03-13","current":-16.382746,"twenty":-22.306698,"median":-17.753166,"eighty":-16.993207,"marketCap":307553178.63},{"date":"2026-03-20","current":-16.957011,"twenty":-22.250635,"median":-17.753166,"eighty":-16.888553,"marketCap":316207550},{"date":"2026-03-27","current":-15.785094,"twenty":-21.714925,"median":-17.597437,"eighty":-16.837477,"marketCap":291516280},{"date":"2026-04-02","current":-18.89617,"twenty":-20.942507,"median":-17.535145,"eighty":-16.702393,"marketCap":347270760},{"date":"2026-04-10","current":-10.676925,"twenty":-19.970755,"median":-17.441707,"eighty":-16.494872,"marketCap":340718966},{"date":"2026-04-17","current":-10.464421,"twenty":-19.238183,"median":-17.254832,"eighty":-16.110604,"marketCap":336672423},{"date":"2026-04-24","current":-9.863583,"twenty":-18.837636,"median":-17.005665,"eighty":-12.953446,"marketCap":318058323},{"date":"2026-05-01","current":-9.064424,"twenty":-18.587877,"median":-16.950192,"eighty":-10.62677,"marketCap":293779061},{"date":"2026-05-08","current":-9.632569,"twenty":-18.344939,"median":-16.86331,"eighty":-10.287304,"marketCap":311583853},{"date":"2026-05-15","current":-9.34654,"twenty":-18.295105,"median":-16.834362,"eighty":-10.043494,"marketCap":300253531},{"date":"2026-05-22","current":-9.812417,"twenty":-18.145605,"median":-16.66306,"eighty":-9.800918,"marketCap":297825605},{"date":"2026-05-29","current":-7.287863,"twenty":-18.008563,"median":-16.66306,"eighty":-9.72533,"marketCap":220902522},{"date":"2026-06-05","current":-7.091826,"twenty":-17.902667,"median":-16.382746,"eighty":-9.634252,"marketCap":213468303},{"date":"2026-06-12","current":-6.717699,"twenty":-17.87775,"median":-16.216296,"eighty":-9.423447,"marketCap":200723927},{"date":"2026-06-18","current":-7.855923,"twenty":-17.87775,"median":-15.872071,"eighty":-9.364073,"marketCap":232584867},{"date":"2026-06-26","current":-6.880017,"twenty":-17.753166,"median":-13.39003,"eighty":-9.064424,"marketCap":202847989},{"date":"2026-07-02","current":-7.524736,"twenty":-17.753166,"median":-10.756935,"eighty":-7.674051,"marketCap":221964554},{"date":"2026-07-10","current":-6.687968,"twenty":-17.753166,"median":-10.600843,"eighty":-7.470839,"marketCap":197537832},{"date":"2026-07-17","current":-5.950494,"twenty":-17.703333,"median":-10.394273,"eighty":-7.2635,"marketCap":177359237},{"date":"2026-07-24","current":-5.990968,"twenty":-17.616125,"median":-10.19196,"eighty":-7.15871,"marketCap":177890252},{"date":"2026-07-31","current":-5.701372,"twenty":-17.597437,"median":-10.084942,"eighty":-7.057391,"marketCap":170260212},{"date":"2026-08-07","current":-6.137986,"twenty":-17.522687,"median":-9.917992,"eighty":-6.810664,"marketCap":183029728},{"date":"2026-08-14","current":-6.239509,"twenty":-17.454165,"median":-9.793252,"eighty":-6.730479,"marketCap":187286234},{"date":"2026-08-21","current":-4.207016,"twenty":-17.441707,"median":-9.728074,"eighty":-6.591693,"marketCap":189239834},{"date":"2026-08-28","current":-5.61745,"twenty":-17.34827,"median":-9.659831,"eighty":-6.31363,"marketCap":251065348},{"date":"2026-09-04","current":-5.551208,"twenty":-17.285978,"median":-9.555453,"eighty":-6.177212,"marketCap":249452508},{"date":"2026-09-11","current":-5.179874,"twenty":-17.261061,"median":-9.448244,"eighty":-6.142393,"marketCap":232248887},{"date":"2026-09-18","current":-5.512013,"twenty":-17.186311,"median":-9.401978,"eighty":-6.005849,"marketCap":244076376},{"date":"2026-09-25","current":-4.959579,"twenty":-17.080415,"median":-9.355306,"eighty":-5.930873,"marketCap":217195718},{"date":"2026-09-30","current":-4.730282,"twenty":-17.005665,"median":-9.17019,"eighty":-5.866178,"marketCap":206443455}],"updateTime":1790925630921},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGEN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638510128","title":"NervGen Pharma files $250M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2638510128","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638510128?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:28","pubTimestamp":1779802110,"startTime":"0","endTime":"0","summary":"09:28 EDT NervGen Pharma (NGEN) files $250M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving bre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-files-250m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-files-250m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638510867","title":"NervGen Pharma Increases Mixed Shelf Offering to $250 Mln From $150 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638510867","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638510867?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:28","pubTimestamp":1779802100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638115375","title":"NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291","url":"https://stock-news.laohu8.com/highlight/detail?id=2638115375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638115375?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:39","pubTimestamp":1779795589,"startTime":"0","endTime":"0","summary":"NervGen Pharma (NGEN) announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-announces-biomechanical-gait-analyses-on-recovery-with-nvg-291-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-announces-biomechanical-gait-analyses-on-recovery-with-nvg-291-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN","NVG","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638519375","title":"NervGen says NVG-291 improves gait quality in Phase 1b/2a chronic tetraplegia study","url":"https://stock-news.laohu8.com/highlight/detail?id=2638519375","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638519375?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:15","pubTimestamp":1779794124,"startTime":"0","endTime":"0","summary":"NervGen reported new independent, blinded gait-analysis results from its Phase 1b/2a CONNECT SCI trial of NVG-291 in chronic tetraplegia.The analysis indicated patients on NVG-291 showed signs consistent with genuine neural recovery, not compensatory movement, versus placebo.The findings support earlier reported improvements across multiple functional measures, reinforcing the program’s clinical signal in a chronic population.The update underpins plans to start the Phase 3 RESTORE registrational study in mid-2026, with site activation underway.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLrj2p9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4588","NDAQ","BK4007","SG9999014013.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","SG9999014005.SGD","BK4112","BK4585","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014021.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638519311","title":"NervGen Pharma Corp - Nvg-291 Shows Statistically Significant Gait Quality Improvement in Phase 1B/2a Connect Sci Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2638519311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638519311?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:15","pubTimestamp":1779794121,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230FT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638315519","title":"NervGen Pharma Corp - on Track to Initiate Phase 3 Restore Study in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638315519","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638315519?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:15","pubTimestamp":1779794121,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230FT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638408304","title":"NervGen Pharma (NGEN) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2638408304","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638408304?lang=en_us&edition=fundamental","pubTime":"2026-05-25 02:15","pubTimestamp":1779646539,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Justin Keywood reiterated a Buy rating on NervGen Pharma on May 21 and set a price target of $6.00. Keywood covers the Heal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nervgen-pharma-ngen-receives-a-buy-from-stifel-nicolaus-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nervgen-pharma-ngen-receives-a-buy-from-stifel-nicolaus-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NGEN","SF","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637319930","title":"BUZZ-U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2637319930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637319930?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:41","pubTimestamp":1779450076,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nL6N41Z0Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1935043536.SGD","SG9999001176.USD","LU2089984988.USD","LU0859254822.USD","LU2360107168.USD","LU2517655028.SGD","LU2491049909.HKD","SG9999014542.SGD","LU1037948541.HKD","BK4017","LU1699723380.USD","IE00B4R5TH58.HKD","LU2468319806.SGD","LU2237438978.USD","BK4534","LU1291159041.SGD","LU0058720904.USD","LU1981816686.USD","LU2023250504.SGD","LU2210149790.SGD","LU1571399168.USD","LU1066053197.SGD","QBTX","EL","BK4581","QBTS","LU1934455194.USD","LU1037948897.HKD","LU0348767384.USD","LU1988902786.USD","LU0266013472.USD","LU1804176565.USD","LU1983299246.USD","LU0211331839.USD","LU0965508806.USD","LU2125154778.USD","LU1066051498.USD","LU2491050071.SGD","BK4504","IE00B5949003.HKD","LU0320765646.SGD","LU0965509283.SGD","LU1861558580.USD","LU1941712264.USD","LU2125909247.SGD","LU0477156953.USD","LU1201861249.SGD","SGXZ57979304.SGD","ZM","LU1823568750.SGD","SG9999002224.SGD","LU2361045086.USD","TTWO","BK4085","BK4139","RGTI","NGEN","LU0985320562.USD","LU1691799644.USD","LU2517655374.HKD","LU0861579265.USD","LU1585245621.USD","LU2106854487.HKD","BK4588","LU2506952170.USD","LU0690374615.EUR","IE0002141913.USD","LU0265550946.USD","LU0690374961.EUR","LU0942090050.USD","LU1061106388.HKD","LU2361044865.SGD","BK4551","BK4127","LU0320765489.SGD","BK4516","BK4524","LU1989773731.SGD","LU2290526834.HKD","LU2506951958.HKD","BK4505","BK4550","LU0082616367.USD","LU2112291526.USD","BK4554","BK4585","IE0009355771.USD","LU0640476718.USD","BK4613","ROST","BK4023","LU1069347547.HKD","BK4526","BK4509","LU2491050154.USD","LU1861215975.USD","LU1923622614.USD","LU2264538146.SGD","IE00B1BXHZ80.USD","LU2506952097.USD","SG9999001176.SGD","PPTA","SG9999014575.USD","LU1861220033.SGD","IE00BLSP4239.USD","LU0868494617.USD","LU1093756325.SGD","BK4007","IE00BJT1NW94.SGD","QBTZ","LU1093756168.USD","LU0208291251.USD","IE00BLSP4452.SGD","RGTZ","LU1917777945.USD","LU0950375773.USD","LU0098860793.USD","LU2506951875.HKD","LU0122379950.USD","BK4535","LU1048588211.SGD","LU1235294995.USD","BK4559","LU1974910355.USD","BK4155","LU2125909593.SGD","SG9999013999.USD","SG9999015341.SGD","BK4525","RGTU","RGYY","BK4141","LU2324357040.USD","LU1046421795.USD","LU2265009873.SGD","LU2461242641.AUD","IE0004445239.USD","LU1023059063.AUD","BK4558","SG9999002232.USD","IE00BN8TJ469.HKD","LU0980610538.SGD","LU2023250843.SGD","BK4183","IE00BFTCPJ56.SGD","LU2357627491.SGD","LU2517655291.USD","IE00BJJMRZ35.SGD","LU1066051811.HKD","LU1989763005.USD","LU0130102774.USD","LU0265550359.USD","LU0432979614.USD","LU2360032135.SGD","IE00BBT3K403.USD","LU2404859741.USD","LU0965509010.AUD","LU2125154935.USD","LU1066051225.USD","SG9999014559.SGD","LU2361044949.HKD","LU0234572021.USD","LU1934455277.USD","MRK","LU0130517989.USD","LU1941712348.USD","BK4608","LU0719512351.SGD","FUTG","LU0823417737.USD","BK4094","QBY","IE000M9KFDE8.USD","LU1280957306.USD","BK4503","BK4532","LU1116320737.USD","LU1989772840.SGD","LU0823417653.USD","LU1934455863.HKD","LU0203347892.USD","LU0061475181.USD","FUTU","LU1861559042.SGD","IE00B2B36J28.USD","LU0868494708.USD","BK4528","LU0203345920.USD","LU0648001328.SGD","LU0348766576.USD","LU1989772923.USD","LU2095319765.USD","LU0072462343.USD","LU0289739699.SGD","LU1162221912.USD","DNLI","BK4548","LU0314104364.USD","LU2552382058.USD","LU1935042991.SGD","LU0238689110.USD","BK4566","LU2433249047.HKD","LU0106261372.USD","LU1057294990.SGD","LU2210150020.SGD","RGTX","LU0081259029.USD","LU1430594728.SGD","WDAY","LU2552382132.HKD","BJ","BK4602","LU0006306889.USD","SG9999015358.SGD","LU1323610961.USD","IE00BSNM7G36.USD","LU1064131342.USD","BK4533","SG9999014567.USD","LU1929549753.HKD","LU0965509101.SGD","LU1989771016.USD","SG9999002463.SGD","SG9999001440.SGD","LU2552382215.SGD","LU1035773651.USD","LU2404859667.USD","LU0070302665.USD","IE0009356076.USD","LU1718418525.SGD","LU1116320901.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637331869","title":"BUZZ-NervGen Pharma tumbles on deep-discounted $60 mln equity raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2637331869","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637331869?lang=en_us&edition=fundamental","pubTime":"2026-05-22 17:51","pubTimestamp":1779443507,"startTime":"0","endTime":"0","summary":"BUZZ-NervGen Pharma tumbles on deep-discounted $60 mln equity raise** NervGen Pharma NGEN.O shares tumble 29.3% premarket to $2.60, a six-month low, after $60 mln follow-on priced at steep discount** Canadian biotech late Thurs sold 24 mln shares with warrants to buy up to 24 mln shares at $2.50, a 32% discount to last sale** The 5-yr warrants are exercisable immediately with exercise price of $3.68** NGEN has ~82.2 mln shares outstanding, per LSEG data** Co intends to use net offering proceeds to fund advancement of its spinal cord injury drug, NVG-291, through clinical studies and for general corporate and working capital purposes** Leerink and TD Cowen joint bookrunners ** Through Thurs, NGEN shares lost 34% YTD** All 7 analysts rate the stock \"buy\"; median PT $8.20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nL6N41Z0ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637391152","title":"NervGen Pharma Shares Down 22.3% at $2.86 Premarket After Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2637391152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637391152?lang=en_us&edition=fundamental","pubTime":"2026-05-22 16:04","pubTimestamp":1779437091,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nL4N41Z0MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637186362","title":"BRIEF-Nervgen Says Co. Announces Pricing Of US$60.0 Million Public Offering Of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2637186362","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637186362?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:28","pubTimestamp":1779420528,"startTime":"0","endTime":"0","summary":"BRIEF-Nervgen Says Co. Announces Pricing Of US$60.0 Million Public Offering Of SecuritiesMay 21 (Reuters) - NervGen Pharma Corp NGEN.O:NERVGEN ANNOUNCES PRICING OF US$60.0 MILLION PUBLIC OFFERING OF S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nTUA3TYWNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637629743","title":"NervGen Announces Pricing of US$60.0 Million Public Offering of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2637629743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637629743?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:27","pubTimestamp":1779420420,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nTUA3TYWNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637621383","title":"NervGen Pharma Corp - Common Shares Sold at $2.50 per Share and Warrant","url":"https://stock-news.laohu8.com/highlight/detail?id=2637621383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637621383?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:27","pubTimestamp":1779420420,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nTUA3TYWNN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637368530","title":"NervGen Pharma secondary offering; price range $2.50-$3.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2637368530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637368530?lang=en_us&edition=fundamental","pubTime":"2026-05-22 06:50","pubTimestamp":1779403811,"startTime":"0","endTime":"0","summary":"18:49 EDT NervGen Pharma (NGEN) secondary offering; price range $2.50-$3.68 Published first on TheFly – the ultimate source for real-time, market-m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-secondary-offering-price-range-2-50-3-68-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-secondary-offering-price-range-2-50-3-68-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357687","title":"NervGen Pharma Shares Slide After Disclosing Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357687","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357687?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:13","pubTimestamp":1779397980,"startTime":"0","endTime":"0","summary":"Shares of NervGen Pharma slid after the company commenced an underwritten public offering of common shares and warrants.The stock declined 17% to $3.06 in after-hours trading Thursday. Shares, which began trading on Nasdaq in January, had lost more than 14% of their value in the past three months through the regular session's close.The company, which is developing neuroreparative therapeutics for spinal cord injuries, didn't detail the size of the offering. It said it intends to use proceeds from the sale to advance one of its in-development treatments through clinical studies, as well as for general corporate and working capital purposes.Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637351926","title":"NervGen Pharma launches underwritten public offering of shares and warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2637351926","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637351926?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:01","pubTimestamp":1779393684,"startTime":"0","endTime":"0","summary":"NervGen launched an underwritten public offering of common shares with accompanying warrants to buy common shares.Some investors may receive pre-funded warrants in lieu of common shares, also paired with common share warrants.Proceeds earmarked to advance NVG-291 through clinical studies, with the remainder for general corporate purposes.Leerink Partners, TD Cowen named as joint bookrunners.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL99qj13:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2V16.EUR","NGEN","LU2210150020.SGD","MNSH","LU2095319765.USD","SG9999014039.USD","SG9999014013.SGD","LU2210149790.SGD","BK4007","BK4112","IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4207","BK4588","IE00B3QW5Z07.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637511633","title":"NervGen Pharma Corp - Net Proceeds to Advance Nvg-291 Clinical Studies and for General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2637511633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637511633?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:01","pubTimestamp":1779393660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA8WBGNY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637351953","title":"NervGen Announces Proposed Public Offering of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2637351953","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637351953?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:01","pubTimestamp":1779393660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA8WBGNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637351168","title":"NervGen Pharma Corp - Commences Underwritten Public Offering of Common Shares, Warrants, and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2637351168","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637351168?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:01","pubTimestamp":1779393660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA8WBGNY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636020302","title":"NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2636020302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636020302?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:15","pubTimestamp":1779102900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA4CPV4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":58,"code":"91000000","status":"200"}]}}